[1]陈 勐.氟喹诺酮类药物的禁忌证、不良反应及临床合理用药对策[J].医学信息,2018,31(19):145-147.[doi:10.3969/j.issn.1006-1959.2018.19.044]
　CHEN Meng.Contraindications and Adverse Reactions of Fluoroquinolones and their Countermeasures for Rational Use of Drugs in Clinical[J].Medical Information,2018,31(19):145-147.[doi:10.3969/j.issn.1006-1959.2018.19.044]
点击复制

氟喹诺酮类药物的禁忌证、不良反应及临床合理用药对策()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年19期
页码:
145-147
栏目:
药物与临床
出版日期:
2018-10-01

文章信息/Info

Title:
Contraindications and Adverse Reactions of Fluoroquinolones and their Countermeasures for Rational Use of Drugs in Clinical
文章编号:
1006-1959（2018）19-0145-03
作者:
陈 勐
江西省万载县中医院药剂科，江西 万载 336100
Author(s):
CHEN Meng
Department of Pharmacy,Wanzai Traditional Chinese Medicine Hospital,Wanzai 336100,Jiangxi,China
关键词:
氟喹诺酮类药物; 禁忌症; 不良反应; 临床合理用药
Keywords:
Fluoroquinolone; Contraindications; Adverse reactions; Clinical rational use of drugs
分类号:
R978.1
DOI:
10.3969/j.issn.1006-1959.2018.19.044
文献标志码:
A
摘要:
目的 研究氟喹诺酮类药物的禁忌证以及不良反应并采取有效的临床用药对策。方法 抽取2016年10月~2018年3月在我院接受氟喹诺酮类药物治疗并出现不良反应的患者275例，回顾性分析氟喹诺酮类药物不良反应患者性别、年龄情况、给药途径、给药方式、不同年龄段患者不良反应发生时间以及恢复时间、不良反应累及器官以及组织。结果 男性患者出现不良反应发生率高于女性患者，31~40岁患者出现不良反应的比率高于其他年龄段患者，静脉注射为主要给药途径，所占比率高于其他给药方式，单独用药比率高于联合用药，18~30岁、31~40岁年龄段患者不良反应发生时间长于其他年龄段患者，恢复时间短于其他年龄段患者，皮肤系统不良反应发生率高于其他系统以及器官不良反应发生率，差异有统计学意义（P＜0.05）。18~30周岁年龄段患者与31~40岁年龄段患者不良反应发生时间、恢复时间，差异无统计学意义（P＞0.05）。结论 临床应用氟喹诺酮类药物时必须严格掌握药物适应证以及禁忌证并确定最佳给药途径和方式，尽量抑制不合理用药发生率，以提升用药安全性。
Abstract:
Objective To study contraindications and adverse reactions of fluoroquinolones and to take effective clinical countermeasures.Methods A total of 275 patients who received fluoroquinolone therapy and had adverse reactions in our hospital from October 2016 to March 2018 were retrospectively analyzed for gender,age,route of administration, and mode of administration of fluoroquinolone adverse reactions.The time of adverse reactions and recovery time,adverse reactions involving organs and tissues in patients of different ages.Results The incidence of adverse reactions in male patients is higher than that in female patients.The incidence of adverse reactions in patients aged 31~40 years is higher than that in other age groups.Intravenous injection is the main route of administration,and the proportion is higher than other modes of administration.The rate of drug use alone was higher than that of combination therapy.Patients with 18 to 30 years old and 31 to 40 years old had longer adverse reactions than other age groups.The recovery time was shorter than that of other age groups.The incidence of adverse reactions in the skin system was higher than that in other systems and organ adverse reactions,and the difference was statistically significant(P<0.05).There was no significant difference in the time and recovery time of adverse reactions between patients aged 18~30 years and those aged 31~40 years(P>0.05).Conclusion The clinical application of fluoroquinolone drugs must strictly control the indications and contraindications of the drug and determine the optimal route and mode of administration,and try to inhibit the incidence of irrational drug use to improve the safety of drug use.

参考文献/References:

[1]尹剑辉.氟喹诺酮类药物的禁忌证不良反应及临床合理用药对策[J].中国药物与临床,2018,18(3):465-466. [2]冯亚奇.氟喹诺酮类药物不良反应及合理用药分析[J].临床医学研究与实践,2017,2(16):28-29. [3]陈霞.氟喹诺酮类药物的不良反应及合理用药分析[J].中国医药指南,2014,12(32):196-197. [4]张晶晶.氟喹诺酮类药物的不良反应分析及临床用药指导[J].中国继续医学教育,2017,9(15):146-148. [5]周兴碧.氟喹诺酮类药物不良反应分析及合理用药对策[J].现代中西医结合杂志,2013,22(28):3138-3140. [6]胡耀中.氟喹诺酮类药物的不良反应及合理用药分析[J].中国医药指南,2016,14(13):83-83,84. [7]田晓燕.浅析氟喹诺酮类药物的不良反应及合理用药[J].保健文汇,2017(8):113,132. [8]黄颢.氟喹诺酮类药物不良反应及合理应用分析[J].临床合理用药杂志,2018,11(9):89-90. [9]徐华涛.氟喹诺酮类药物临床不良反应及合理用药分析[J].现代医药卫生,2014,30(24):3765-3766. [10]吴静.65例氟喹诺酮类抗生素不良反应的临床探讨分析[J].中国医药指南,2016,14(28):107.

相似文献/References:

[1]沈孟杰.氟喹诺酮类药物临床应用的不良反应与用药原则研究[J].医学信息,2018,31(15):135.[doi:10.3969/j.issn.1006-1959.2018.15.043]
　SHEN Meng-jie.Adverse Reactions and Principles of Drug Use in Clinical Application of Fluoroquinolones[J].Medical Information,2018,31(19):135.[doi:10.3969/j.issn.1006-1959.2018.15.043]
[2]何广伟.氟喹诺酮类药物在结核病治疗中的研究进展[J].医学信息,2019,32(07):64.[doi:10.3969/j.issn.1006-1959.2019.07.020]
　HE Guang-wei.Research on Fluoroquinolones in the Treatment of Tuberculosis[J].Medical Information,2019,32(19):64.[doi:10.3969/j.issn.1006-1959.2019.07.020]

更新日期/Last Update: 2018-10-29